Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth has maintained an Overweight rating on WAVE Life Sciences and raised the price target from $11 to $22.
October 16, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has increased its price target for WAVE Life Sciences from $11 to $22, maintaining an Overweight rating, indicating a positive outlook.
The increase in price target from $11 to $22 by Wells Fargo suggests a strong positive outlook for WAVE Life Sciences. The Overweight rating indicates that the analyst expects the stock to outperform its peers. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100